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Abstract and learning objectives:
The purpose of this article is to review:
1. Factors influencing long-term outcome data after
transplantation
2. Patient survival overall, the effect of recipient age and
donor type, causes of death, comparison of mortality
after transplantation with that on dialysis, and effect of
pre-emptive transplantation and race
3. Transplant survival overall, and the effect of recipient
and donor age, donor type, pre-emptive transplantation,
recurrent diseases, human leukocyte antigen (HLA)
matching, immunosuppression, concordance, hyperten-
sion, bladder dynamics and type of donor nephrectomy
4. Final height and obesity
5. Psycho-social outcome
Keywords Long-termoutcome.Mortality.Graftsurvival.
Growth.Psycho-social
Introduction
The first paediatric renal transplantations took place in the
1970s. During the 1980s there was a steady increase in num-
bers, and there has been relative stabilisation since 2000, such
that now most registries report that approximately two-thirds of
children and adolescents on end-stage renal failure (ESRF)
programmes have a transplant [1–4]. Studies of outcome over
20 years are now beginning to emerge [1, 5–9]. Such
information is of considerablei m p o r t a n c ei no r d e rf o ru st o
counsel patients and families. However, we have to remember
that we cannot assume to be able to extrapolate directly from
these data to the current day. This is because changes over the
years have had both positive and negative influences: ad-
vances in technical and therapeutic knowledge and the
increasing numbers of families that are coming forward for
living donation (LD) have to be balanced against the accep-
tance of more and more challenging patients onto ESRF
programmes, including neonates and children with severe, and
sometimes life threatening, co-morbidity [10]. What is consis-
tently demonstrated is that there has been an improvement in
outcome over the years [1, 11–13]. Clearly, it is rather artificial
for us to consider long-term outcome only in patients with
transplants, as most will switch treatment modalities over such
a time span. Still, such data are important in order to provide
comparative results between dialysis and transplantation,
information which will influence management decisions.
Factors influencing outcome data
Long-term outcome data will be affected by several factors.
Available resources [7, 14] affect patient selection, follow-
up and drug regimens. Community attitudes influence
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neonates and children with handicaps [15]. Some diagnoses
are more common in particular ethnic backgrounds [2]o r
even countries (e.g. Finnish-type nephrotic syndrome), and
patient and graft survival are affected by racial group [11].
Figures will also be affected by the proportion of LD, for
which outcome is generally superior. Countries vary in the
size of their LD programmes. Some centres use only LDs
[16], whereas percentages differ considerably between both
European countries and the USA. What is clear is that an
increasing number of families are opting for LD, presum-
ably as a result of information showing its superior results,
at least over the first 5 years, the increasing understanding
of the complications of dialysis, and the ability to plan the
timing of the transplantation. For example, LDs provided
43% of all transplants in the USA between 1987 and 1991,
52% between 1987 and 2004, and, since 1998, have
accounted for 58%. Of these donors, 82% were parents
(56% mothers, 44% fathers) [17].
Patient survival
The number of children on the waiting list for deceased
donor (DD) transplantation has increased slowly over the
past decade, despite an increasing proportion of LD. The
mortality rate of children on the waiting list over the same
time period has been low and has declined to 55 per 1000 at
risk [18]. However, the overall mortality rate remains high,
with a relative risk of death after transplantation that is
12.7-times higher than that of the age-related general
population [1], with little sign of improvement since the
1980s [4, 19]. Although these values may be due to
changing patient selection, they remain unacceptably high.
Overall patient survival
Overall 5-year patient survival varies between 70% and
100% at 5 years [1, 5–7, 9, 12, 13, 16, 18, 20–26], 75% to
95% at 10 years [1, 7, 9, 12, 18, 21, 23–26], 83% to 94% at
15 years [1, 27], 54% to 86% at 20 years [1, 5, 7] and there
is one report of 81% 25-year patient survival [6].
Effect of recipient age
Ageisanimportantfactorthathasbeendemonstratedtoaffect
patient survival, although there is evidence that its effect has
declined in recent years. Several early reviews showed
increased mortality in young children and, particularly, in
those under 2 years of age at transplantation: in two studies
there was a mortality rate of 21% [5, 28]; however, more
recently, survival rates of over 98% have been reported [29,
30]. Increased risk of death was also seen to extend up to age
5 years at transplantation: Dutch data showed that the
mortality rate was nearly twice as high in those under 5
years of age than in those 6 to 10 years old [19]; in a review
of children with an average age of 4.7 years who weighed
<20 kg at transplantation, 19% were reported to have died
[23]. A reduction in mortality rate has occurred in this age
range too, with a halving of the mortality rate between the
1970s and 1980s in the Dutch report [19], a mortality rate of
8.2% unaffected by age less than or older than 5 years at
transplantation [1], a 5-year survival rate of over 97% in
under 6 year olds [31], a 91% 10-year survival rate in those
weighing <15 kg [25], and 87% 15-year survival in those
<11 kg at transplantation [32]. Most studies have small
numbers of subjects, making statistics and interpretation
difficult; however, what does seem to be the case is that
deaths in those who had received transplants before they
were 5 years old occur sooner after transplantation (indeed
all the deaths in the younger age group were in those less
than 15 years of age) than in those that had received
transplants when they were over this age [1].
Effect of donor type
All reports show a small but consistent benefit of LD on
mortality at all ages up to 5 years after transplantation [1,
12, 13, 18]. However, thereafter, there are few long-term
data available, with one centre showing a benefit [12] and
one not [1] at 10 years after transplantation. The survival
rate for recipients of LDs has been improving over time: in
the USA it was 96.1% 5 years after transplantation,
between 1995 and 2004, and was 94.7% between 1987
and 1994; for infants, 3-year survival rates have improved
from 88.4% between 1987 and 1994 to 94.9% since 1995.
LD has a particular benefit for the very young child: 5-year
patient survival rates for recipients less than 2 years old was
86% following living related donation (LRD) and 70%
following DD transplantation [17].
Causes of death after transplantation
The major causes of death after transplantation are
cardiovascular disease (CVD), infection and malignancy,
variously reported as 30–36% for CVD, 24–56% for
infection and 11–20% for malignancy [19, 21, 22, 27].
CVD has been defined in different ways, some studies
including cerebrovascular events and arrhythmias as part of
the definition. However, despite this, results are remarkably
similar between centres, and, overall, CVD is the most
common, and potentially preventable, cause of death.
Infection, both sepsis related and due to opportunistic
organisms, is becoming more of a problem with the use of
more powerful immunosuppression. Malignancy is ten-
times more common than expected for age [33, 34]a n d
also might be expected to increase in incidence with
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Skin cancer is the most frequent, accounting for approxi-
mately 60% of all cancers, but it does not contribute to
mortality. Non-Hodgkin’s lymphoma represents about a
quarter of cases and is the commonest cancer to cause
death. Most patients do not present until they have been
moved to adult units; by 25 years after first renal
replacement therapy (RRT), the probability of developing
a malignancy is 17%, with a peak incidence at 15 years
[34]. In some children risk may be heightened by
syndromes associated with a genetic predisposition to
cancer. The overall mortality rate, if Epstein–Barr virus
(EBV)-driven post-transplantation lymphoproliferative dis-
ease (PTLD) is included, is 20%, and is associated with a
20% risk of graft failure [35].
Two other important factors that contribute to death are
non-concordance with medications, or treatment withdraw-
al [1], and obesity [36]. Obese children aged 6 to 12 years
had a higher risk of death than non-obese patients (adjusted
relative risk 3.65 for LD; 2.94 for DD), and death was more
likely to be as a result of cardiopulmonary disease (27% in
obese children, 17% in non-obese children).
Comparison of mortality after transplantation
with mortality on dialysis
All studies show a survival advantage for patients who
receive transplants in comparison with those who undergo
dialysis, be that peritoneal (PD) or haemodialysis (HD): the
lifespan of a child on dialysis is 40–60 years less, and, for a
child with a transplant, 20–25 years less, than that of age-
and race-matched general populations [37]. Eighty percent of
patients on HD, 83% of those on PD and 93% of those with
a transplant survive 5 years, according to the latest (2006)
United States Renal Data System (USRDS) data [3].
Mortality rates are seven-times higher in those who have
been on dialysis for longer than they have had a transplant
[38], and treatment with dialysis is associated with a risk
more than four-times as high as for renal transplantation [4].
Most of the increased mortality in children on dialysis is
due to CVD; indeed, prolonged stay on dialysis is the most
important risk factor for CVD. USRDS data from 1990 to
1996 among patients who started ESRF therapy as children
and had died before they were 30 years of age showed that
transplant recipients had a 78% lower risk of cardiac death
than did dialysis patients. The cardiac death rate among
dialysis patients was approximately 21 per 1,000 patient-
years, whereas after transplantation, values were under 2
per 1,000 patient-years [39]. CVD accounts for 57% of
deaths of those on HD, 43% of those on PD and 30% of
those with a transplant [4].
It might be expected, therefore, that patient survival after
pre-emptive transplantation would be superior, although,
conceivably, this might be difficult to demonstrate, as, for
many children, the period of dialysis is only short. Euro-
transplant identified a superior survival at 6 years in
patients who received pre-emptive LD kidneys in compar-
ison to LD after dialysis, but no difference in those
receiving DD kidneys [40]. The North American Pediatric
Renal Transplant Cooperative Study (NAPRTCS) showed
that adolescents who had undergone pre-emptive transplan-
tation had a better survival rate [41].
Effect of race
US registries demonstrate poorer outcomes for Afro-
Americans than for the white population. Most of this dif-
ference can be accounted for by an increased incidence of
cardiovascular deaths by approximately 1.6 times. Between
1990 and 1996, of patients who started RRTas children and
had died before they were 30 years of age, the percentage of
cardiac deaths was higher among black patients at all ages:
0–4y e a r s ,3 6 % ;5 –9y e a r s ,1 8 % ;1 0 –14 years, 35%; 15–
19 years, 22%; 20–30 years, 32%; white patients 18%,
12%, 17%, 14%, and 23%, respectively. Among black
patients, cardiac deaths occurred in 11% of transplant
recipients and 34% of dialysis patients, and, among white
patients, 9% and 25%, respectively [3, 11, 39, 42].
Transplant survival
Overall transplant survival
Transplant survival has shown a steady increase over the
years [1, 12, 16, 42]. The earliest transplants, prior to 1983,
had only a 20% 10-year survival [1]. Over the next decade,
following the introduction of ciclosporin, there was an
improvement to 45% [1], and this percentage has continued
to increase since, to as high as 95% at 10 years in one
centre [12]. However, we are still seeing the effects of the
early poor success rates: 25% of the early transplants failed
at 5 years, yielding a projected half-life of 10 years. Given a
median age at transplantation of 13 years, 50% of all
current paediatric kidney recipients will need a second graft
before the age of 25 years [11].
Overall 5-year transplant survival varies between 44% to
95% [1, 7–9, 12, 14, 18, 21, 23–26, 30]a t5y e a r s ,2 3 % –95%
at 10 years [1, 7–9, 12, 21, 23–26, 30] ,3 5 %a t1 5y e a r s[ 8]
and 21–36% at 20 years [1, 6, 8].
Graft survival of repeat transplants has been reported as
being equal to or slightly reduced that of first grafts [1, 43].
When DDs were used, graft survival rates at 1, 3 and
5 years were 79%, 69%, and 62%, compared with 74%,
60%, and 47%, respectively, for the repeat transplants; for
LDs, they were 91%, 83%, and 76% compared to 86%,
78%, and 72%, respectively, for repeat transplants [43].
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Age has an important influence on the transplant as well on
as patient survival. Until recently, young age was consid-
ered to be the most important predictor of outcome: the
United Network for Organ Sharing (UNOS) has shown
graft survival of 71% and 60% at 1 year and 5 years in
those under the age of 2 years at transplantation, 83% and
64% in those aged 3 to 12 years and 85% and 57% in those
aged 13 to 21 years [44]. Others have reported similar
values for under fives of 67.7% at 1 year, 57.4% at 5 years
and 45.2% at 10 years [30]. UK Transplant demonstrated
increased risk of early transplant loss, principally due to
technical difficulties, in those under 2 years of age,
although after this age risk was equal to that in older
children [22]. More recent UNOS data has shown that
younger age and earlier era of transplantation adversely
affect transplant outcome and gave an odds ratio of 2 for
increased risk of graft loss in 2 to 5 year olds in comparison
with 6 to 12 year olds [42]. However, in the past decade,
the effect of young age has become less, such that children
under 10 years of age now have the best long-term graft
and patient survival rates of all recipients [1, 18]. Causes of
graft loss are different in the youngest children, when
surgical issues such as venous and arterial thromboses and
urological problems predominate. This means that the large
proportion of transplant loss is in the first few months after
transplantation at this age [20].
Age becomes important again in adolescents, who, as a
group, have the worst graft survival rate of all ages [18, 22,
40, 45]. Adolescents have a high percentage of late acute
rejection episodes and relatively poor rejection reversal
outcomes, compared to the other age groups, suggesting
that lack of compliance with immunosuppressive regimens
may be an important contributory factor [45]. Non-
concordance contributes significantly to transplant loss at
this age [22, 46]. However, not only non-concordance may
account for the increased graft loss: adolescents have a
relatively high incidence of focal segmental glomeruloscle-
rosis(FSGS)(12.3%ofcausesofESRF),withdecreasedgraft
survival, compared to younger children with FSGS [47].
Effect of donor age
Kidneys from deceased donors aged 11–17 years do best,
with a 73% 5-year survival rate [18]. Some studies have
warned of the increased risk of graft thrombosis in young
patients when young donors, particularly under 5 years of
age, are used [22, 25], although others have reported equal
outcome, with transplant survival of 55% after 5 years, for
donors <6 years of age, and of 60% for donors over that age
[48], suggesting that the restriction of kidney selection to
donors aged >6 years may not be justified. The Italian
registry suggests a lower cut-off age of 24 months [31].
More recently, the 5-year graft survival rate from donors
<1 year of age has risen to 60% (equal to that of donors
aged >50 years of age) and to 70% for donors aged 1 year
to 5 years [18]. Therefore, it may be that the use of small
kidneys is appropriate in selected patients.
Effect of donor type
Living related donation (LRD) has been shown to benefit
outcome, with results of 75% and 85% at 10 years,
compared to 46% for DDs [12, 49]. Belgian data showed
10% better transplant survival over DD kidneys [21].
Others have shown a benefit of LRD kidneys in the first
5 years after transplantation, although this benefit was lost
by 10 years [1]. Possible explanations for this are that non-
concordance and the effects of calcineurin inhibitor-induced
nephrotoxicity have taken effect by this time and affect
recipients of LRD kidneys equally with those receiving DD
kidneys. It has been calculated that a 10-year-old child who
received a renal transplant in 2000 and is receiving
ciclosporin-based immunosuppression can expect a trans-
plant half-life of 13.1 years from an LRD and 10.8 years
from a DD [1], although for LD recipients with no acute
rejection episodes, half-life has been calculated to be as
high as 37.6 years [49].
LRD is of particular benefit to the recipient under 2 years
of age. Five-year graft survival for recipients under 2 years
old was 86% following LRD and 38% following DD
transplantation. Recipients aged between 2 and 18 years
over the same time period had a 5-year graft survival rate of
73% following LRD, which was similar to that for
recipients less than 2 years of age in this study [20].
Effect of pre-emptive transplant
NAPRTCS data show that transplant survival is improved
in patients receiving a pre-emptive transplant compared
with those undergoing PD and HD. Graft loss resulting
from vascular thrombosis is more common in children who
undergo PD than in those who on HD [50]. Eurotransplant
found a difference in graft survival between those not on
dialysis and those on dialysis of 82% and 69%, respective-
ly, at 6 years [40].
It has been postulated that the delaying of transplantation
in adolescents may lead to improved adherence, but this is
at the cost of longer time on dialysis. The Australia and
New Zealand Dialysis and Transplant Registry (ANZ-
DATA) confirmed that 5- and 10-year graft survival rates
were significantly worse in adolescents (65% and 50%,
respectively) than in recipients aged 2 to 10 years (74% and
58%) and 20 to 29 years (72% and 57%). However, waiting
time on dialysis was an independent risk factor for failure
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were associated with a 50% reduction in the risk of graft
failure. Delaying transplantation in adolescents may expose
them to increased risk of poorer outcomes [51].
Recurrent diseases
Diseases that recur after transplantation and, therefore, have
a potential to affect outcome include FSGS, membranopro-
liferative glomerulonephritis (MPGN) and haemolytic urae-
mic syndrome (HUS) [42, 47, 52, 53]. Oxalate will continue
to be deposited in the transplant if liver transplantation is
not undertaken in patients with hyperoxaluria. Nephrotic
syndrome can recur in patients with congenital nephrotic
syndrome, and anti-glomerular basement membrane (anti-
GBM) nephritis in patients with Alport’s syndrome, both
due to the development of antibody to the ‘missing’ protein.
FSGS is the most feared of all, as it recurs in approximately
30% of transplants, conferring a relative risk of transplant
loss of 1.27 in comparison to other diseases [42, 47, 54].
Readers are referred to a review of this subject [55].
Human leukocyte antigen matching
Donor-specific HLA mismatching is a risk for poor
outcome [17]. Worst outcome has been observed for two
HLA-DR mismatched grafts, while 000 and favourably
matched kidneys (100, 010, 110 HLA-A, -B, -DR mis-
matches) survived longest [56]. Sensitised patients [panel
reactive antibodies (PRA)>40%] [11] also have a poorer
outcome, and donor antigen-specific hyporeactivity corre-
lates with better graft function [57].
Immunosuppression
There have been considerable changes in the use of
immunosuppression over the years. NAPRTCS has reported
that the use of ciclosporin has decreased from 82.3% in 1996
to 20.7% in 2003. In contrast, use of tacrolimus has
increased from 5.5% to 67.1% over the same period. There
has also been a move away from azathioprine (AZA), from
56.4% to 1.9%, towards mycophenolate mofetil (MMF), use
of which is now approximately 57.4%. Antibody induction
has also moved away from antithymocyte globulins (ATGs)
and OKT3 to anti-IL2 receptor blockers. The use of steroid-
sparing regimens is also becoming common [17].
Clearly, changes in immunosuppression to more powerful
agents over the years will have affected transplant outcome.
There is evidence that the use of MMF in association with
ciclosporin is associated with better outcome at 5 years than
a similar regimen using AZA, transplant survival’s being
90.7% for MMF and 68.5% for AZA patients. Cumulative
rejection-free survival was also better in the MMF group, at
51.2% versus 37.0% in AZA patients [58]. As absence of
rejection is associated with better outcome [49], the
projected half-life was 14.4/4.5 years in patients with
rejection and 18.7/14.5 years without rejection in the
MMF/AZA groups, respectively [58].
There is also evidence that tacrolimus is more effective
than ciclosporin: a randomised trial of steroids and
azathioprine with either tacrolimus or ciclosporin demon-
strated that tacrolimus was significantly more effective than
ciclosporin in both preventing acute rejection and main-
taining graft function, with a 4-year transplant survival rate
of 86% and 69%, respectively, and glomerular filtration
rates (GFRs) of 71.5 ml/min/1.73 m
2 and 53.0 ml/min/
1.73 m
2 body surface area, respectively [59].
Concordance with therapeutic regimens
Non-concordance with therapeutic regimens is a difficult
problemtodealwith.Itaffectspatientsandfamiliesatallages,
but particularly so at adolescence. A study of concordance
evaluated by cyclosporine levels, attendance at clinic visits,
individual interviews and unexplained late graft dysfunction
identified that non-concordance was the main factor in late
graft loss, accounting for 71% of cases, and was a particular
problem in Afro-American recipients [60].
Hypertension
Hypertension is very common after transplantation, and its
incidence varies with time, ranging from 46%, 40%, and 66%
of children at 1, 5, and 10 years, respectively [9]. Other
studies give similar results [8, 33, 61]. The presence of
hypertension is a significant and independent predictor of
poor long-term transplant function, regardless of the number
of rejection episodes or transplant function at 1 year [62].
Bladder dynamics
Transplantation into an abnormal urinary tract is associated
with a high incidence of urological and infectious compli-
cations [63]. However, despite this, several studies have
found no effect on patient survival or transplant outcome
[63–66]. Based on a review of 25 articles on the subject, it
has been suggested that bladder reconstruction should be
performed before transplantation when clinically indicated
[66], although one study suggests that there is no adverse
outcome on long-term allograft survival or function from
transplantation into the unaugmented valve bladder [67].
Because of the high urological complication rates, careful
surveillance of lower urinary tract function by urodynamic
evaluation is essential before transplantation. Reflux does
not need to be corrected before transplantation, unless it is
causing symptoms or infection [68–70].
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Laparoscopic donor nephrectomy is associated with a longer
operationtimeandlongerwarmischaemiaandcoldischaemia
times in LDs than is the open approach [71]. However, the
number of hospitalisation days and the use of analgesia in
laparoscopy donors are lower, and there are no differences in
complications between the techniques. Most importantly,
graft outcome does not seem to be affected [72].
Final height and incidence of obesity
Final height is another factor that is influenced by the era of
transplantation: improvements in pre-transplantation man-
agement, particularly nutrition, have led to a better height
attainment at transplantation, which is recognised as one
of the most important factors in final height achievement
[73]. Furthermore, the decline in steroid dosing as immu-
nosuppression has also has a positive benefit on growth.
Most studies report reduced final height in patients who
underwent transplantation in childhood, with up to 44%
below the normal range in early reports, improving to
25% more recently [6, 9]. Some studies include patients
that have received recombinant human growth hormone
(rHGH) and suggest that final height is better than for
those not receiving it [74]. Median final heights for women
and men, respectively, who did not receive rhGH, were
147.4 and 156.6 cm [75]. They were 151.0 cm [median
standard deviation score (SDS) −1.9] and 162.7 cm
(median SDS −1.8) in a study containing some patients
on rhGH [76], and 156 cm and 165 cm in patients who all
received rhGH [77].
However, one study reports good growth in children
who did not receive growth hormone: a median height
of 158 cm and 166 cm, respectively, for girls and boys
older than 17 years, was reduced, in comparison with
that of the general population, but it was within the nor-
mal range, even though some patients had been treated
with the higher doses of steroids used before ciclosporin
was available. Many of the patients that had received
transplants in the later years of the review period were still
only 17 years old, so they may not have attained their final
height [1].
Obesity, defined by a body mass index (BMI) >95th
centile, is increasing in the transplant population (12.4%
after 1995 and 8% before 1995) [36], and seems to be more
common in girls [61].
Psychosocial outcome
In spite of a high re-transplantation rate and the presence of
significant morbidity, renal transplantation in children can
lead to attainment of a productive and satisfying life, with a
high degree of rehabilitation in adulthood. It has to be
remembered, however, that most studies are based on
returns of questionnaires, which inevitably leads to selec-
tion bias. Psychosocial outcome seems to be better after
transplantation than for patients on dialysis [78].
Employment
Several studies have revealed satisfactory employment
levels, reported as follows: 81% employed [1]; 61.5% able
to work, 43.4% working [79]; 86% employed [6]; 73%
employed versus 72% in the general population, and 6.5%
unemployed versus 10.5% in the general population, and
18.7% receiving a disablement pension [75]; 82%
employed [33]; and 72% in paid work [80]. The range of
occupations is broad, with a normal average working time
each week; 91% were satisfied with their ability to perform
at work or school, and only 5% were dissatisfied [81].
Relationships
Successful relationships are reported in the majority of
studies [80, 81] as follows: 50% married, and the
overwhelming majority reported satisfaction in their sexual
lives [33]; 50% of women and 27% of men married [72];
67% of women and 25% of men married [1]; and 40%
married, 27% had children [80]. The striking observation,
however, was the very low incidence of men with children,
both overall (7%) and in comparison with the women
(24%), both in London [1], in the French study, when 8.3%
of men had offspring in comparison to 27% of the women
[75]. The cause of this finding is unclear.
In the US study, 89% were satisfied with life in general,
95% said health never or seldom interfered with family life,
and 95% felt that health and drug side effects were of no or
minor concern in sexual relationships. Only 3% felt that
health was a problem in maintaining a sexual relationship
(41% were not sexually active). Only 4% stated that health
often interfered with their social life; 98% met friends on a
regular basis; 76% were satisfied with personal relation-
ships, and 8% were dissatisfied [81].
Physical morbidity
In a US study of those who had undergone transplantation
between 1967 and 1999, nearly half were severely short
and 27% were obese. Rates of hypertension, bone and joint
symptoms, fractures, hypercholesterolaemia, and cataracts
were high. In spite of significant remaining health issues,
95% reported their health as “fair” or “good”, 61% reported
“no” or “minor” physical limitations, and 82% described
themselves as “just as” or “more content than others” [33].
Co-morbidity was found in 40% of all patients in the Dutch
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19%. Bone disease, headaches, itching, and tremors were
the most reported disabling problems [8]. Other complica-
tions included osteoporosis in 53% of patients, avascular
bone necrosis in 13%, post-transplantation diabetes mellitus
in 10%, and hypertension in 60% [82]. In the study from
Norway, minor cataracts without visual disturbance were
found in 45% of patients [9]. Sensorineural hearing loss
was documented in 18% of patients receiving transplants
before the age of 5 years in Finland, and 15% received anti-
convulsive treatment after transplantation [83]. In Germany,
27% suffered from additional disabilities [6]. In the USA,
health-related absence from work was non-existent for
93%. Health was rated as good to excellent by 91% and fair
by 9%. The future was regarded as hopeful or promising by
80% [81].
Education
In the French study the distribution of educational level
was lower than national averages: 27.4% were at the
lowest level versus 3% of the general population, 41.4%
were at the middle level, 31.2% had reached the bac-
calaureate level, and 11% had followed a university
course [75]. Compared with that of all age-matched Dutch
inhabitants, educational attainment was low [8]. In Finland,
79% of children who had undergone transplantation before
the age of 5 years attended ordinary schools and 76% had
normal motor performance. The mean intelligence quotient
(IQ) was 87, and 6–24% showed impairment in neuropsy-
chological tests [83]. Patients’ scores on achievement tests
were influenced by age at diagnosis and by the mother/
caregiver’s lower achievement [84].
Independence
In the French study, 46% lived in their parents’ home and
54% lived independently. There was a correlation between
educational level, paid activity, marital life, and indepen-
dent housing with final height [75]. Rates of dependency on
parents were also high in the Dutch study [8].
Conclusion
Transplantation is the treatment of choice for children with
ESRF. It offers the best chances for growth, development
and quality of life, and is associated with a lower mortality
risk than is dialysis, particularly that due to CVD. For these
reasons, many paediatric nephrologists aim for pre-emptive
transplantation for their patients, and more and more
families are coming forward as potential LDs for their
children.
Questions (answers appear after references)
For each question (a) to (e), answer true or false
1. Factors that positively influence long-term outcome:
(a) Analysis of cohorts since the 1980s in comparison
to before that
(b) Non-Caucasian race
(c) Proportion of LDs
(d) Co-morbidity
(e) A high proportion of adolescents
2. Patient survival:
(a) LD is of particular benefit to those under 2 years
of age
(b) Deaths occur much later after transplantation in
those who received transplants before they were
5 years of age than after this age
(c) Cause of death is most commonly malignancy
(d) The incidence of infections as a cause of death is
increasing
(e) Is adversely affected by obesity
3. Cardiovascular disease
(a) Isthecommonestcauseofdeathaftertransplantation
(b) Has a lower incidence in dialysis patients than in
post-transplantation patients
(c) Is a more common cause of death in Afro-
Americans than in the white population
(d) Hypertension is uncommon after transplantation
(e) Is likely to become more common, given the
increasing incidence of obesity after transplantation
4. Transplant survival
(a) Is much worse in very young children, according
to the latest data
(b) Recurrence of FSGS has a worse prognosis in
adolescents than in younger children
(c) LD transplant survival is superior to DD transplant
survival in the first 5 years after transplantation
(d) Is superior in pre-emptive transplants in adolescents
(e) Is unaffected by HLA matching
5. Psychosocial and other factors
(a) There is no evidence for improving height prog-
nosis over the years
(b) Laparoscopic donor nephrectomy has a negative
effect on graft outcome
(c) Bone disease is the commonest cause of post-
transplantation morbidity
(d) Most studies have not shown an adverse effect of
abnormal bladder dynamics on outcome
(e) Generally, reports of psychosocial outcomes are
disappointing
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Answers
1. (a)=t; (b)=f; (c)=t; (d)=f; (e)=f
2. (a)=t; (b)=f; (c)=f; (d)=t; (e)=t
3. (a)=t; (b)=f; (c)=t; (d)=f; (e)=t
4. (a)=f; (b)=t; (c)=t; (d)=t; (e)=f
5. (a)=f; (b)=f; (c)=t; (d)=t; (e)=f
(t=true; f=false)
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